All In Biotech

NDA 020779 · Agouron Pharms

Viracept

Nelfinavir Mesylate · Oral

NovelAccelerated approvalPriority review

Last checked: Nov 19, 2026Latest source record: Mar 24, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Mar 14, 1997

Approved uses

4

Original approval plus efficacy supplements

Registered trials

144

24 Phase 3, 3 recruiting

FAERS reports

2,091

1,922 serious, 110 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 11, 2025.

VIRACEPT in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection. VIRACEPT is a protease inhibitor indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents. ( 1 )

Mechanism: Nelfinavir is an inhibitor of the HIV-1 protease [see Microbiology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 19, 2004 Supplement 42 · Efficacy · priority review ReviewLabelLetter
  • May 17, 2000 Supplement 26 · Efficacy Review
  • Nov 24, 1999 Supplement 22 · Efficacy ReviewLetter
  • Mar 14, 1997 Original approval · Type 1 - New Molecular Entity · priority review Review
1 products under this application
  • VIRACEPT · NELFINAVIR MESYLATE EQ 250MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Nelfinavir" as an intervention, any sponsor and status, largest first.

All 144 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug exposure during pregnancy414
  • pain243
  • anxiety236
  • emotional distress236
  • anhedonia210
  • foetal exposure during pregnancy203
  • chronic kidney disease140
  • osteoporosis137
  • anaemia120
  • bone density decreased115
  • premature baby115
  • depression110

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004194
2005209
2006199
2007161
200883
200993
2010209
2011101
201251
201329
201431
201595
201691
201729
201846
2019130
2020145
2021105
202242
202319
20241
20258
20265

Recalls

1 FDA enforcement reports for this application.

  • Jul 8, 2014 · Class III · Terminated

    Labeling: Incorrect or missing lot and or Exp Date: The bottles were labeled with an incorrect expiry date 11/2016. The correct expiry date is 09/2016.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Viracept (Nelfinavir Mesylate)

2024 spending

$705K

Beneficiaries

64

515 claims

Per beneficiary

$11,019

$9.63 per unit

View as table
YearSpending
2020$1,431,046
2021$1,279,965
2022$1,144,770
2023$909,064
2024$705,212

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 310 on PubMed

Sponsor: Agouron Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.